Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1755)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (13)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4172)
  2. Weinberg Fellows (2756)
  3. Hematologic Malignancies, Division of (2492)
  4. Solid Tumor Oncology Division (2422)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (343)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4491)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intestinal microbiota injury during allo-HSCT is generalizable across transplantation centers and is associated with increased mortality, broad-spectrum antibiotics, and decreased calorie intake
    Meeting Abstract

    Peled, J. U.; Gomes, A.; Buchan, M. L.; Stein-Thoeringer, C. K.; Slingerland, J. B.; Slingerland, A. E.; Weber, D.; Sung, A. D.; Maloy, M.; Peets, T.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Long-term follow-up of adult double unit cord blood (CB) transplantation (dCBT) recipients reveals high rates of progression-free survival after a novel cy/flu/thio/TBI 400 intermediate intensity conditioning regimen
    Meeting Abstract

    Politikos, I.; Devlin, S. M.; Jacob, A.; Maloy, M.; Mazis, C.; Naputo, K.; Scaradavou, A.; O'Reilly, R.; Avecilla, S.; Castro-Malaspina, H. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • More intensive fludarabine/busulfan (Flu/Bu) conditioning regimens result in similar outcomes without adding serious toxicity when compared to fludarabine/melphalan (Flu/Mel) in patients undergoing allogeneic hematopoietic cell transplant (Allo-HCT)
    Meeting Abstract

    Pappacena, J.; Bhatt, V.; Shah, G. L.; Hilden, P.; Maloy, M.; Buie, L. W.; Giralt, S. A.; Scordo, M.
    Blood (2017)

    Fulltext@MSK | Save
  • SETBP1 and NRAS mutations are frequent events in post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) lacking JAK-STAT activating mutations
    Meeting Abstract

    Menghrajani, K.; Rapaport, F.; McNamara, C. J.; Devlin, S. M.; Famulare, C.; Patel, M.; Medina, J.; Sandy, L.; Kosiorek, H.; Singer Weinberg, R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ex vivo T cell-depleted and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival survival: On behalf of the ALWP of the EBMT and the MSKCC
    Meeting Abstract

    Malard, F.; Labopin, M.; Cho, C.; Blaise, D.; Papadopoulos, E. B.; Passweg, J. R.; O'Reilly, R.; Milpied, N.; Maloy, M.; Volin, L.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genetically-defined AML subgroups represent diverse epigenetic heterogeneity landscape
    Meeting Abstract

    Li, S.; Chen, X.; Wang, J.; Meydan, C.; Glass, J. L.; Shih, A. H.; Valk, P. J. M.; Delwel, R.; Levine, R. L.; Mason, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Characteristics and outcome of patients with acute myeloid leukemia and t(6;9)(p22;q34)
    Meeting Abstract

    Kayser, S.; Hills, R. K.; Luskin, M. R.; Brunner, A. M.; Shaw, C.; Westermann, J.; Menghrajani, K.; Baer, M. R.; Elliott, M. A.; Perl, A. E.; more...
    Blood (2017)

    Fulltext@MSK | Save